Hospira Cisplatin 50mg/50ml Concentrate for Infusion vial

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

cisplatin, Quantity: 1 mg/mL

Available from:

Hospira Australia Pty Ltd

INN (International Name):

Cisplatin

Pharmaceutical form:

Injection, intravenous infusion

Composition:

Excipient Ingredients: mannitol; sodium chloride; water for injections; sodium hydroxide; hydrochloric acid

Administration route:

Intravenous Infusion

Units in package:

1 X 50mL

Class:

Medicine Listed (Export Only)

Prescription type:

(S1) This Schedule is intentionally blank

Therapeutic indications:

Cisplatin is indicated in metastatic, non seminomatous germ cell carcinoma, advanced stage and refractory ovarian carcinoma, advanced stages of refractory bladder carcinoma, advanced stages of refractory bladder carcinoma and squamous cell carcinoma of the head and neck. Cisplatin is indicated in combination with other antineoplastic agents for the treatment of metastatic testicular tumors.

Product summary:

Visual Identification: A clear, colourless to pale yellow solution, free from visible particulates; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Authorization status:

Licence status A

Authorization date:

2009-03-10